Xtl Biopharmaceuticals (XTLB) EBITDA Margin (QoQ) (2011 - 2018)
Xtl Biopharmaceuticals (XTLB) EBITDA Margin (QoQ) (2011 - 2018) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn |
| 10 | Xtl Biopharmaceuticals | 2.51 Bn | 2.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -63,380.00 |
| Jun 30, 2018 | 51,855.00 |
| Sep 30, 2017 | -9,101.00 |
| Jun 30, 2017 | 11,250.00 |
| Sep 30, 2014 | -2,182.00 |
| Jun 30, 2014 | -20,725.00 |
| Mar 31, 2014 | -317.00 |
| Dec 31, 2013 | -7,090.00 |
| Sep 30, 2013 | 37,058.00 |
| Jun 30, 2013 | -5,817.00 |
| Mar 31, 2013 | -4,387.00 |
| Dec 31, 2012 | -4,517.00 |
| Sep 30, 2012 | 9,036.00 |
| Jun 30, 2012 | -16,652.00 |
| Mar 31, 2012 | 6,035.00 |
| Dec 31, 2011 | 8,208.00 |
| Sep 30, 2011 | -4,695.00 |